|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...19202122232425262728293031» |
- |||| Agriflu (trivalent influenza virus vaccine) / CSL Behring
Trial completion, Preclinical: Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions (clinicaltrials.gov) - Dec 4, 2011
P4, N=1398, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed
- rosuvastatin / Generic mfg.
Enrollment change: STIP: Statin Trial for Influenza Patients (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=7, Terminated, Sponsor: Gordon Bernard
Active, not recruiting --> Completed N=2000 --> 7
- |||||||||| New P3 trial: Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults (clinicaltrials.gov) - Nov 27, 2011
P3, N=1701, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- |||||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
New P3 trial: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (clinicaltrials.gov) - Nov 24, 2011
P3, N=1315, Completed, Sponsor: Sanofi Pasteur MSD
- | paracetamol / Generic mfg.
Trial completion: Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu (clinicaltrials.gov) - Nov 24, 2011
P3, N=216, Completed, Sponsor: Hospital de Clinicas de Porto Alegre
N=2000 --> 7 Recruiting --> Completed
- ||| Enrollment change: Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™ (clinicaltrials.gov) - Nov 17, 2011
P2, N=192, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=93 --> 192
- ||| Trial completion: Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines (clinicaltrials.gov) - Nov 15, 2011
P1, N=72, Completed, Sponsor: Novartis Vaccines
N=93 --> 192 Active, not recruiting --> Completed
- ||||||| Fluzone (influenza vaccine) / Sanofi
Trial completion: Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age (clinicaltrials.gov) - Nov 14, 2011
P3, N=3116, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment change: Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects (clinicaltrials.gov) - Nov 14, 2011
P2, N=125, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=60 --> 125
- Rapivab (peramivir) / BioCryst
Enrollment change: Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza (clinicaltrials.gov) - Nov 9, 2011
P1/2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=60 --> 125 N=63 --> 0
- |||||||||| New P3 trial: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age (clinicaltrials.gov) - Nov 8, 2011
P3, N=175, Completed, Sponsor: Novartis Vaccines
- ||||||| FluLaval Quadrivalent (influenza vaccine) / GSK
Trial completion: A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older (clinicaltrials.gov) - Nov 3, 2011
P3, N=112, Completed, Sponsor: GlaxoSmithKline
N=63 --> 0 Active, not recruiting --> Completed
- Trial completion: A Study to Describe Pediatric Influenza Vaccine Coverage (clinicaltrials.gov) - Nov 3, 2011
P=N/A, N=0, Completed, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine (clinicaltrials.gov) - Nov 2, 2011
P1, N=24, Completed, Sponsor: University of Oxford
- ||||||| Trial completion: Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants (clinicaltrials.gov) - Oct 27, 2011
P3, N=660, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Avian Influenza Studies In Lebanon (clinicaltrials.gov) - Oct 25, 2011
P=N/A, N=250, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: OIDA: A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=300, Completed, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- |||||||||| New P3 trial: A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold (clinicaltrials.gov) - Oct 24, 2011
P3, N=120, Completed, Sponsor: Hyben Vital ApS
- |||||||||| Relenza (zanamivir) / GSK, Vaxart
New P3 trial: Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China (clinicaltrials.gov) - Oct 23, 2011
P3, N=298, Completed, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- ||| Trial completion, Preclinical: Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine (clinicaltrials.gov) - Oct 23, 2011
P=N/A, N=556, Completed, Sponsor: Novartis Vaccines
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China (clinicaltrials.gov) - Oct 23, 2011
P3, N=670, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People (clinicaltrials.gov) - Oct 20, 2011
P=N/A, N=256, Completed, Sponsor: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Completed
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Rotarix (rotavirus vaccine) / GSK
Trial completion: Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (clinicaltrials.gov) - Oct 20, 2011
P2, N=480, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Rapivab (peramivir) / BioCryst
Trial withdrawal: Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza (clinicaltrials.gov) - Oct 19, 2011
P1/2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Withdrawn
- |||||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (clinicaltrials.gov) - Oct 19, 2011
P3, N=80, Completed, Sponsor: GlaxoSmithKline
- |||||||||| Pediarix (diphtheria, tetanus toxoids and acellular pertussis adsorbed, hepatitis b and inactivated poliovirus vaccine) / GSK, Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately (clinicaltrials.gov) - Oct 19, 2011
P3, N=440, Completed, Sponsor: GlaxoSmithKline
- ||||| New P4 trial: A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season (clinicaltrials.gov) - Oct 19, 2011
P4, N=52, Completed, Sponsor: Crucell Holland BV
- oseltamivir / Generic mfg.
New P4 trial: Time to Oseltamivir Access When Prescribed by Pharmacists Versus Physicians (ACCESS) (clinicaltrials.gov) - Oct 18, 2011
P4, N=48, Terminated, Sponsor: Trial Management Group Inc.
- Trial completion: Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children (clinicaltrials.gov) - Oct 18, 2011
P=N/A, N=10, Completed, Sponsor: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Recruiting --> Withdrawn Active, not recruiting --> Completed
- ||| Trial completion: Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine (clinicaltrials.gov) - Oct 18, 2011
P=N/A, N=355, Completed, Sponsor: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- busulfan / Generic mfg., decitabine / Generic mfg.
New P1 trial, Combination therapy: PRO#0118: Decitabine Plus Mini Flu-Bu (clinicaltrials.gov) - Oct 18, 2011
P1, N=20, Completed, Sponsor: Hackensack University Medical Center
- |||| Trial completion: Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly (clinicaltrials.gov) - Oct 17, 2011
P2, N=130, Completed, Sponsor: NasVax Ltd
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Rapivab (peramivir) / BioCryst
P2 data, Enrollment change: A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza (clinicaltrials.gov) - Oct 16, 2011
P2, N=405, Completed, Sponsor: BioCryst Pharmaceuticals
Not yet recruiting --> Completed N=320 --> 405
- ||| oseltamivir / Generic mfg.
Trial completion: Oseltamivir Infant Influenza Safety Study (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=900, Completed, Sponsor: Charite University, Berlin, Germany
N=320 --> 405 Active, not recruiting --> Completed
- New P1 trial: Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients (clinicaltrials.gov) - Oct 13, 2011
P1, N=60, Enrolling by invitation, Sponsor: Vanderbilt University
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P4 trial: Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (clinicaltrials.gov) - Oct 12, 2011
P4, N=494, Completed, Sponsor: GlaxoSmithKline
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
New P2 trial: Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly (clinicaltrials.gov) - Oct 12, 2011
P2, N=312, Completed, Sponsor: GlaxoSmithKline
- oseltamivir / Generic mfg.
Enrollment open: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults (clinicaltrials.gov) - Oct 11, 2011
P=N/A, N=800, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: FMRESP: A Study of a Live Intranasal Influenza Vaccine in Children With Cancer (clinicaltrials.gov) - Oct 11, 2011
P1, N=56, Completed, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment open: ResPECT: The Respiratory Protection Effectiveness Clinical Trial (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=1600, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Trial completion, Preclinical: Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects (clinicaltrials.gov) - Oct 10, 2011
P3, N=126, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- ||||||| Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi, Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old (clinicaltrials.gov) - Oct 10, 2011
P3, N=954, Completed, Sponsor: Sanofi Pasteur MSD
Not yet recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment change: Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=135469, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=9000 --> 135469
- ||| Trial completion: Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=135469, Completed, Sponsor: Novartis Vaccines
N=9000 --> 135469 Active, not recruiting --> Completed
- ||||||| Trial completion: Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age (clinicaltrials.gov) - Oct 10, 2011
P3, N=778, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age (clinicaltrials.gov) - Oct 10, 2011
P3, N=752, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Pilot Study of Genotypic Analysis (clinicaltrials.gov) - Oct 6, 2011
P=N/A, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=10 --> 6
- |||||||||| Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK
New P3 trial: Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine (clinicaltrials.gov) - Oct 6, 2011
P3, N=831, Completed, Sponsor: GlaxoSmithKline
- Enrollment change: Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=104, Completed, Sponsor: St. Jude Children's Research Hospital
N=10 --> 6 N=400 --> 104
- Trial completion: Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=104, Completed, Sponsor: St. Jude Children's Research Hospital
N=400 --> 104 Active, not recruiting --> Completed